Search This Blog

Thursday, September 3, 2026

Aptevo Phase 1b data with mipletamig triplet show 79% CR/CRi, 93% clinical benefit in AML

 

Aptevo Therapeutics reports Phase 1b RAINIER data with mipletamig triplet showing 79% CR/CRi and 93% clinical benefit in TP53-mutated frontline AML

  • Mipletamig triplet nearly doubled published venetoclax/azacitidine remission outcomes in high‑risk TP53-mutated frontline AML population.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)